Clinical and Neurobiological Effects of Cannabis Dependence in Young Adults
NCT ID: NCT00656487
Last Updated: 2017-06-19
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
66 participants
INTERVENTIONAL
2008-04-30
2011-01-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antagonist-Elicited Cannabis Withdrawal
NCT01041170
The Neural Correlates of Cannabis Use
NCT03104257
Effects of Citicoline on Brain Function and Behavior in Marijuana-Dependent Individuals
NCT00158249
Treatment for Cannabis Withdrawal and Dependence
NCT01611948
Pharmacological Treatment of Comorbid Alcohol and Marijuana Withdrawal and Dependence
NCT02210195
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cannabis-dependent rimonabant
Cannabis dependent young adults administered rimonabant 90 mg at Day 0 and followed for 28 days post.
rimonabant
double blind, placebo controlled, single 90 mg dose
Cannabis-dependent placebo
Cannabis dependent young adults administered matched placebo at Day 0 and followed for 28 days post.
placebo
matched placebo
Non-cannabis using control
Non-cannabis using demographically similar young adults followed for 28 days.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rimonabant
double blind, placebo controlled, single 90 mg dose
placebo
matched placebo
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* meets Diagnostic and Statistical Manual (DSM-IV) diagnosis of Cannabis Dependence
* willing to be abstinent for 28 days during study
* smokes \< 10 cigarettes per day
* drinks \< 1 (female) or \< 2 (male) per day
Exclusion Criteria
* meets DSM-IV diagnosis for dependence on other substances other than cannabis
* significant medical disorders
* pregnant women
* meets DSM-IV diagnosis for a major Axis I disorder other than cannabis dependence
* currently taking psychoactive medication
21 Years
30 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
The Scripps Research Institute
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Barbara J. Mason
PI
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Barbara J Mason, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
The Scripps Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Scripps Research Institute
La Jolla, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DA024194
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.